Eric S. Kilpatrick

ORCID: 0000-0003-1676-0461
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian function and disorders
  • Diabetes Management and Research
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Diabetes Treatment and Management
  • Diabetes and associated disorders
  • Hormonal and reproductive studies
  • Lipid metabolism and disorders
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Reproductive Biology and Fertility
  • Phytoestrogen effects and research
  • Gestational Diabetes Research and Management
  • Diet, Metabolism, and Disease
  • Cardiovascular Function and Risk Factors
  • Liver Disease Diagnosis and Treatment
  • Growth Hormone and Insulin-like Growth Factors
  • Pharmacology and Obesity Treatment
  • Chronic Kidney Disease and Diabetes
  • Metabolism, Diabetes, and Cancer
  • Hormonal Regulation and Hypertension
  • Diet and metabolism studies
  • Lipoproteins and Cardiovascular Health
  • Ovarian cancer diagnosis and treatment
  • Diabetes Management and Education
  • Fatty Acid Research and Health
  • Retinal Diseases and Treatments

Manchester University NHS Foundation Trust
2020-2024

Weill Cornell Medical College in Qatar
2024

Manchester Royal Infirmary
1998-2023

Bahrain Center for Strategic International and Energy Studies
2023

Sidra Medical and Research Center
2016-2020

Hull Royal Infirmary
2006-2018

Hull York Medical School
2007-2015

Hull and East Yorkshire Hospitals NHS Trust
2005-2015

University of Hull
2005-2015

Castle Hill Hospital
2015

The presence of insulin resistance and the metabolic syndrome are known risk markers for macrovascular disease in patients with without type 2 diabetes. This study has examined whether these also were predictors micro- complications 1 diabetic participating Diabetes Control Complications Trial (DCCT).International Federation (IDF) criteria used to identify 1,337 Caucasian DCCT at baseline. Insulin was calculated using their estimated glucose disposal rate (eGDR). dose (units/kg) as a...

10.2337/dc06-1982 article EN Diabetes Care 2007-02-27

Debate remains as to whether short- or long-term glycemic instability confers a risk of microvascular complications in addition that predicted by mean glycemia alone. In this study, we analyzed data from the Diabetes Control and Complications Trial (DCCT) assess effect A1C variability on retinopathy nephropathy patients with type 1 diabetes.A1C was collected quarterly during DCCT 1,441 individuals. The SD after stabilization (from 6 months onwards) were compared adjustments for age, sex,...

10.2337/dc08-0864 article EN cc-by-nc-nd Diabetes Care 2008-07-24

It is not known whether glycemic instability may confer a risk of microvascular complications that in addition to predicted by the mean blood glucose (MBG) value alone. This study has analyzed data from Diabetes Control and Complications Trial (DCCT) assess effect variability on retinopathy nephropathy patients with type 1 diabetes.Pre- postprandial seven-point profiles were collected quarterly during DCCT 1,441 individuals. The area under curve SD within 24 h between visits compared...

10.2337/dc06-0293 article EN Diabetes Care 2006-06-26

Phytoestrogen consumption has been shown to reduce risk factors for cardiovascular disease. Type 2 diabetes confers an adverse profile particularly in women after menopause. The aim of this study was determine whether a dietary supplement with soy protein and isoflavones affected insulin resistance, glycemic control, markers postmenopausal type diabetes.A total 32 diet-controlled completed randomized, double blind, cross-over trial supplementation phytoestrogens (soy 30 g/day, 132 mg/day)...

10.2337/diacare.25.10.1709 article EN Diabetes Care 2002-10-01

Whether obesity is associated with a better prognosis in patients type 2 diabetes mellitus controversial.To investigate the association between body weight and large cohort of followed for prolonged period.Prospective cohort.National Health Service, England.Patients diabetes.The relationship mass index (BMI) without known cardiovascular disease at baseline was investigated. Information on all-cause mortality morbidity (such as acute coronary syndrome, cerebrovascular accidents, heart...

10.7326/m14-1551 article EN Annals of Internal Medicine 2015-05-04

Diabet. Med. 27, 1318–1321 (2010) Abstract Aim To examine the effects of chocolate on lipid profiles, weight and glycaemic control in individuals with Type 2 diabetes. Methods Twelve diabetes stable medication were enrolled a randomized, placebo‐controlled double‐blind crossover study. Subjects randomized to 45 g or without high polyphenol content for 8 weeks then crossed over after 4‐week washout period. Changes weight, control, profile high‐sensitivity C‐reactive protein measured at...

10.1111/j.1464-5491.2010.03108.x article EN Diabetic Medicine 2010-08-12

Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular morbidity, whereas statins are proven to reduce mortality and morbidity through lipid-lowering perhaps their pleiotropic effects. Statins can also testosterone in vitro by inhibiting ovarian theca-interstitial cell proliferation steroidogenesis reducing inflammation vivo.Our objective was assess the effect atorvastatin on inflammatory markers, insulin resistance, biochemical hyperandrogenemia patients...

10.1210/jc.2008-1750 article EN The Journal of Clinical Endocrinology & Metabolism 2008-10-22

OBJECTIVE This study analyzed data from the Epidemiology of Diabetes Interventions and Complications (EDIC) to see whether longer-term follow-up Control Trial (DCCT) patients reveals a role for glycemic instability in development microvascular complications. RESEARCH DESIGN AND METHODS The mean area under curve glucose within-day variability (SD amplitude excursions [MAGE]) during DCCT were assessed they contributed risk retinopathy nephropathy by year 4 EDIC. RESULTS Logistic regression...

10.2337/dc09-0109 article EN cc-by-nc-nd Diabetes Care 2009-06-23

Summary Background Empagliflozin is a sodium‐glucose‐cotransporter‐2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type‐2 diabetes. Polycystic ovary syndrome (PCOS) associated obesity increased risk; therefore, empagliflozin may be of benefit for these women. The aim this study was to compare the effects vs metformin on anthropometric body composition, hormonal metabolic parameters women PCOS. Materials methods A randomized open‐label conducted PCOS...

10.1111/cen.13968 article EN Clinical Endocrinology 2019-03-13

This study was designed to assess the biological variability of total testosterone and SHBG in polycystic ovarian syndrome (PCOS) determine use as a surrogate marker insulin resistance PCOS. Fasting blood samples were collected at 4-d intervals on 10 consecutive occasions from 12 PCOS patients 11 age- weight-matched controls. Duplicate analyzed for SHBG, testosterone, single batch, calculated by homeostasis model assessment method (HOMA-IR). The group had higher (mean ± sd, 3.9 0.8 vs. 3.2...

10.1210/jc.2002-020557 article EN The Journal of Clinical Endocrinology & Metabolism 2003-04-01

The objective of this study was to evaluate and compare the effect treatment with orlistat vs. metformin on hormonal biochemical features patients polycystic ovarian syndrome (PCOS). Twenty-one Caucasian women PCOS [mean (±sem) age 27 ± 0.9 yr body mass index 36.7 3.3 kg/m2] participated in prospective, randomized, open-labeled study. All subjects had an 8-wk run-in period dietary modification then randomized receive either (500 mg three times daily) or (120 for 3 months. Weight, blood...

10.1210/jc.2004-0176 article EN The Journal of Clinical Endocrinology & Metabolism 2005-02-01

OBJECTIVE To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control A1C patients with diabetes chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS This was a prospective study type 2 CKD stage IIIB or IV undergoing (group A) and/or ESA B). Full blood profiles were determined over period. Glycemic monitored using A1C, seven-point daily glucose three times weekly, continuous monitoring (CGM). RESULTS There 15 in both group A B. Mean (95%...

10.2337/dc10-0917 article EN cc-by-nc-nd Diabetes Care 2010-08-26

Eric Kilpatrick, Zachary Bloomgarden, and Paul Zimmet question proposals to diagnose diabetes by raised glycated haemoglobin concentration rather than glucose testing

10.1136/bmj.b4432 article EN BMJ 2009-11-10

There is concern whether soy phytoestrogens may affect thyroid function. If true, be expected to have a greater impact in subjects with subclinical hypothyroidism.The primary aim was determine the effect of phytoestrogen supplementation on function, secondary assessing effects cardiovascular risk indices patients hypothyroidism.We conducted randomized, double-blind, crossover study tertiary care setting.Sixty hypothyroidism participated study.Patients were randomly assigned either low-dose...

10.1210/jc.2010-2255 article EN The Journal of Clinical Endocrinology & Metabolism 2011-02-17

In the ongoing search for improved serum markers of impaired renal function (1), low-molecular-weight protein cystatin C has been advocated as a promising and probably superior alternative to creatinine when used assess glomerular filtration rate (GFR) (2)(3). Cystatin possesses most properties an ideal GFR test in that it is produced by all nucleated cells at apparently constant rate, freely filtered glomerulus, then fully destroyed proximal tubule (4). Its production not influenced...

10.1373/49.4.680 article EN Clinical Chemistry 2003-04-01

Previous studies have shown a single linear relationship between mean plasma glucose (MPG) and hemoglobin A(1c) (HbA(1c)). We examined the in different treatment groups of patients with type 1 diabetes participating Diabetes Control Complications Trial (DCCT).Seven-point profiles (premeal, postmeal, bedtime) HbA(1c) were measured quarterly during DCCT. studied measurements from (a) intensively treated at study commencement, (b) after stabilization their glycemia (from 6 months onward), (c)...

10.1373/clinchem.2006.079756 article EN Clinical Chemistry 2007-03-24

Renal impairment is a contraindication to metformin treatment because of the perceived increased risk lactic acidosis. Current guidelines define renal according serum creatinine individual, but this measure being supplanted by use estimated glomerular filtration rate (eGFR) as it gives closer estimate true GFR. This study aimed establish pragmatic eGFR limits for in patients considered treatment.Estimated GFR measurements corresponding currently used 130 and 150 micromol/l were derived then...

10.1111/j.1464-5491.2007.02221.x article EN Diabetic Medicine 2007-08-02

OBJECTIVE Increases in blood pressure and visit-to-visit variability have both been found to independently increase the likelihood of cardiovascular events nondiabetic individuals. This study has investigated whether each may also influence development microvascular complications type 1 diabetes by examining data from Diabetes Control Complications Trial (DCCT). RESEARCH DESIGN AND METHODS Using binary longitudinal multiple logistic regression, mean systolic (SBP) diastolic (DBP) as well...

10.2337/dc10-1000 article EN cc-by-nc-nd Diabetes Care 2010-08-26

Mean insulin resistance (IR) is greater and it also more variable in overweight women with polycystic ovarian syndrome (PCOS) compared to weight matched controls. Whilst treatment will reduce the mean IR, not known if IR variability reduced.To compare change its before after sensitization through metformin pioglitazone, that induced by loss orlistat.Randomized, open labelled parallel study.Endocrinology outpatient clinic at a referral centre.Thirty obese PCOS patients [BMI 36.0 +/- 1.2...

10.1111/j.1365-2265.2008.03309.x article EN Clinical Endocrinology 2008-06-10

Haemoglobin A(1c) (HbA(1c)) is due to celebrate its 40th birthday. Many people would argue that the clinical studies relating test diabetes complications while in late 20s are likely be finest ever achievement. However, this article looks at how HbA(1c) has matured since then and discusses detail many strengths idiosyncrasies as a marker of glycaemic risk have, 30-something, become more clearly understood. As approaches middle age, paper also describes appears developing mid-life crisis,...

10.1136/jcp.2007.054304 article EN Journal of Clinical Pathology 2008-08-28
Coming Soon ...